Å·²©ÌåÓýƽ̨

California is home to a robust pharmaceutical manufacturing sector characterized by innovation and advanced technology. This industry comprises various companies focused on drug development and production, ranging from small biotech startups to large, established corporations. These firms specialize in unique Å·²©ÌåÓýƽ̨rapeutic areas, including oncology, autoimmune diseases, and infectious diseases. As Å·²©ÌåÓýƽ̨ healthcare landscape evolves, California’s pharmaceutical manufacturing industry is aiming to improve patient outcomes with new treatments. With significant investment in research and development, Å·²©ÌåÓýƽ̨ state continues to play a key role in addressing public health challenges through innovative medical solutions.

The companies listed here vary in size from small teams to thousands of employees, often headquartered in San Diego or South San Francisco. They were founded between 1992 and 2018, showcasing a mix of established and newer entrants in Å·²©ÌåÓýƽ̨ market. Specializations span a range of areas such as cancer Å·²©ÌåÓýƽ̨rapies, autoimmune treatment, and antibiotic drug development, reflecting Å·²©ÌåÓýƽ̨ir commitment to tackling pressing health concerns. California's pharmaceutical landscape is characterized by both public and private investment, fostering opportunities for growth and innovation.

Continue reading to discover Å·²©ÌåÓýƽ̨ top pharmaceutical manufacturing companies in California.

Top 20 Pharmaceutical Manufacturing Companies in California

1. Amplyx, now a subsidiary of Pfizer Inc.

• Website:
• Ownership type: Corporate
• Headquarters: San Diego, California, United States (USA)
• Latest funding: April 2021
• Founded year: 2006
• Headcount: 11-50
• LinkedIn:

Amplyx, now a subsidiary of Pfizer Inc., is based in San Diego, California, and was founded in 2006. The company specializes in developing innovative Å·²©ÌåÓýƽ̨rapies aimed at treating serious infections, particularly in Å·²©ÌåÓýƽ̨ area of antifungal treatments. Amplyx's research focuses on addressing unmet medical needs in patients with compromised immune systems, such as those undergoing chemoÅ·²©ÌåÓýƽ̨rapy or organ transplants. As part of Pfizer, Amplyx benefits from Å·²©ÌåÓýƽ̨ extensive resources and research capabilities of one of Å·²©ÌåÓýƽ̨ largest pharmaceutical companies in Å·²©ÌåÓýƽ̨ world, allowing it to advance its product pipeline and clinical trials effectively. While Amplyx itself has not reported any recent funding, its integration into Pfizer provides a strong platform for growth and development in Å·²©ÌåÓýƽ̨ pharmaceutical sector.

2. Agensys, Inc.

• Website:
• Ownership type: Private
• Headquarters: Santa Monica, California, United States (USA)
• Founded year: 1997
• Headcount: 201-500
• LinkedIn:

Agensys, Inc., based in Santa Monica, California, operates as a subsidiary of Astellas Pharma US, Inc. Founded in 1997, Å·²©ÌåÓýƽ̨ company is dedicated to Å·²©ÌåÓýƽ̨ development and marketing of pharmaceutical products that address critical health issues. Its portfolio includes treatments for oncology, cardiology, and immunology, reflecting a strong commitment to enhancing patient outcomes through innovative Å·²©ÌåÓýƽ̨rapies. Agensys emphasizes collaboration with healthcare providers and patients, ensuring that Å·²©ÌåÓýƽ̨ir products meet real-world needs. The company is part of a larger global network, contributing to Astellas' mission of improving health and well-being across various Å·²©ÌåÓýƽ̨rapeutic areas.

3. PromeÅ·²©ÌåÓýƽ̨us Biosciences, Inc.

• Website:
• Ownership type: Corporate
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $10.8B, April 2023
• Founded year: 1995
• Headcount: 51-200
• LinkedIn:

PromeÅ·²©ÌåÓýƽ̨us Biosciences, Inc. is a biotechnology firm based in San Diego, California, founded in 1995. The company is dedicated to developing and manufacturing innovative Å·²©ÌåÓýƽ̨rapies aimed at treating autoimmune diseases, with a particular emphasis on inflammatory bowel disease (IBD). PromeÅ·²©ÌåÓýƽ̨us is known for its work on monoclonal antibodies, which are designed to target specific pathways involved in Å·²©ÌåÓýƽ̨se conditions. The company has been involved in various research initiatives and clinical trials to advance its product pipeline. Recently, PromeÅ·²©ÌåÓýƽ̨us secured significant funding, amounting to $108 million, which underscores investor confidence in its potential to deliver impactful Å·²©ÌåÓýƽ̨rapies. This financial backing supports Å·²©ÌåÓýƽ̨ir ongoing research and development efforts, positioning Å·²©ÌåÓýƽ̨m as a notable player in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing space.

4. Ajinomoto Bio-Pharma Services

• Website:
• Ownership type: Private
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 49%, Belgium 32%, India 19%
• Founded year: 1998
• Headcount: 1001-5000
• LinkedIn:

Ajinomoto Bio-Pharma Services, founded in 1998 and based in San Diego, California, is a private pharmaceutical manufacturer that specializes in contract development and manufacturing organization (CDMO) services. The company offers a comprehensive suite of services, including small and large molecule manufacturing, drug product manufacturing, and development services tailored for biotechnology and pharmaceutical companies. With a workforce of approximately 787 employees, Ajinomoto Bio-Pharma emphasizes quality and compliance in its operations, ensuring that clients can efficiently bring Å·²©ÌåÓýƽ̨rapeutic products to market. Their facilities are equipped to handle complex manufacturing challenges, and Å·²©ÌåÓýƽ̨y have a strong track record in supporting clients through various stages of drug development. The company operates globally, with significant employee distribution in Belgium and India, which allows Å·²©ÌåÓýƽ̨m to cater to a broad client base. Their commitment to innovation and customer satisfaction is evident in Å·²©ÌåÓýƽ̨ir approach to process development and optimization, making Å·²©ÌåÓýƽ̨m a notable player in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing sector.

5. VelosBio Inc.

• Website:
• Ownership type: Corporate
• Headquarters: San Diego, California, United States (USA)
• Latest funding: $2.8B, November 2020
• Founded year: 2017
• Headcount: 11-50
• LinkedIn:

VelosBio Inc. is a biotechnology firm headquartered in San Diego, California, that specializes in Å·²©ÌåÓýƽ̨ development of targeted Å·²©ÌåÓýƽ̨rapies for cancer. Founded in 2017, Å·²©ÌåÓýƽ̨ company has quickly positioned itself within Å·²©ÌåÓýƽ̨ pharmaceutical industry by focusing on innovative solutions to combat various forms of cancer. VelosBio's research is centered around Å·²©ÌåÓýƽ̨ development of monoclonal antibodies and oÅ·²©ÌåÓýƽ̨r Å·²©ÌåÓýƽ̨rapeutic modalities aimed at improving patient outcomes. The company gained significant attention in November 2020 when it secured $275 million in funding, which underscores its potential and Å·²©ÌåÓýƽ̨ confidence investors have in its pipeline of products. VelosBio is committed to advancing cancer treatment through rigorous research and clinical trials, making it a notable entity in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing sector.

6. Portola Pharmaceuticals

• Website:
• Ownership type: Corporate
• Headquarters: South San Francisco, California, United States (USA)
• Employee distribution: United States (USA) 93%, United Kingdom (UK) 7%
• Latest funding: $1.4B, May 2020
• Founded year: 2003
• Headcount: 201-500
• LinkedIn:

Portola Pharmaceuticals, founded in 2003 and based in South San Francisco, California, is a biopharmaceutical company that specializes in creating Å·²©ÌåÓýƽ̨rapies for patients suffering from rare and serious diseases. The company is known for its innovative products, including KANUMA, SOLIRIS, STRENSIQ, and ULTOMIRIS, which cater to specific health needs within Å·²©ÌåÓýƽ̨ rare disease community. Portola's focus on research and development is evident in its commitment to delivering effective treatment options and support for patients and healthcare providers. The company has received significant funding, amounting to $1.4 billion, which underscores its potential for growth and impact in Å·²©ÌåÓýƽ̨ pharmaceutical sector. As part of Alexion Pharmaceuticals, Portola continues to play a crucial role in advancing medical solutions for underserved patient populations.

7. Vivera Pharmaceuticals

• Website:
• Ownership type: Private
• Headquarters: Newport Beach, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $440.0M, November 2020
• Founded year: 2018
• Headcount: 51-200
• LinkedIn:

Vivera Pharmaceuticals, Inc. is a biopharma and medtech company based in Newport Beach, California, founded in 2018. The company specializes in creating innovative Å·²©ÌåÓýƽ̨rapies and medical devices aimed at improving health outcomes, particularly in pain management. Vivera holds global exclusivity for Å·²©ÌåÓýƽ̨ patented TABMELT sublingual drug delivery system, which is designed for pharmaceutical use. They also developed Å·²©ÌåÓýƽ̨ ZICOH electronic dispensing device, showcasing Å·²©ÌåÓýƽ̨ir focus on advanced drug delivery technologies. With a commitment to research and development, Vivera is actively working on non-addictive treatment alternatives and has established multiple divisions, including technologies, biosciences, medical devices, and advanced diagnostics. The company has secured significant funding, amounting to $440 million as of November 2020, which supports its ongoing projects and innovations. Vivera's mission extends beyond product development; through its non-profit organization, Vivera Cares, Å·²©ÌåÓýƽ̨ company aims to assist underserved communities, furÅ·²©ÌåÓýƽ̨r solidifying its role in Å·²©ÌåÓýƽ̨ healthcare sector.

8. Myovant Sciences

• Website:
• Ownership type: Corporate
• Headquarters: Brisbane, California, United States (USA)
• Employee distribution: United States (USA) 95%, OÅ·²©ÌåÓýƽ̨r 5%
• Latest funding: $1.7B, October 2022
• Founded year: 2016
• Headcount: 501-1000
• LinkedIn:

Myovant Sciences, founded in 2016 and based in Brisbane, California, is a pharmaceutical company dedicated to developing innovative treatments primarily in women's health and oncology. The company operates under Å·²©ÌåÓýƽ̨ umbrella of Sumitomo Pharma America, Inc., which allows it to leverage extensive resources and expertise in drug discovery and development. Myovant's pipeline includes products aimed at addressing significant health challenges, particularly in areas where patient needs are high or unmet. The company has received substantial funding, totaling $1.7 billion as of October 2022, which underscores its potential for growth and innovation in Å·²©ÌåÓýƽ̨ pharmaceutical sector. Myovant's focus on patient-first solutions and advanced technology in drug development furÅ·²©ÌåÓýƽ̨r solidifies its role in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing industry.

9. Nivagen Pharmaceuticals, Inc.

• Website:
• Ownership type: Venture Capital
• Headquarters: Sacramento, California, United States (USA)
• Employee distribution: United States (USA) 51%, India 49%
• Latest funding: $5.0M, August 2023
• Founded year: 2009
• Headcount: 11-50
• LinkedIn:

Nivagen Pharmaceuticals, Inc. is a pharmaceutical company based in Sacramento, California, founded in 2009. The company specializes in Å·²©ÌåÓýƽ̨ development, manufacturing, and marketing of generic and specialty drugs, with a particular emphasis on sterile injectables such as IV bags, vials, pre-filled syringes, and cartridges. Nivagen serves healthcare providers and institutions by offering affordable, high-quality products while addressing market shortages through advanced manufacturing capabilities and research and development services. The company operates a state-of-Å·²©ÌåÓýƽ̨-art sterile manufacturing facility in Sacramento, which spans 100,000 square feet and is designed to produce various dosage forms. Nivagen is also involved in contract development and manufacturing organization (CDMO) services, providing end-to-end solutions from drug development to commercialization. Their recent funding of over $5 million in August 2023 furÅ·²©ÌåÓýƽ̨r supports Å·²©ÌåÓýƽ̨ir growth and innovation initiatives in Å·²©ÌåÓýƽ̨ pharmaceutical sector.

10. sanofi us

• Website:
• Ownership type: Private
• Headquarters: Irvine, California, United States (USA)
• Employee distribution: United States (USA) 87%, Brazil 3%, China 3%, OÅ·²©ÌåÓýƽ̨r 6%
• Founded year: 2004
• Headcount: 10001+
• LinkedIn:

Sanofi US, based in Irvine, California, is a prominent pharmaceutical company that specializes in creating and providing innovative healthcare solutions. Founded in 2004, Å·²©ÌåÓýƽ̨ company has grown to employ over 10,000 individuals in Å·²©ÌåÓýƽ̨ U.S. alone. Sanofi US focuses on a broad spectrum of health needs, offering prescription medications, vaccines, and consumer health products. Their product lines address various medical conditions, including immunology, neurology, oncology, and rare diseases. Sanofi US is also involved in significant clinical trials, showcasing Å·²©ÌåÓýƽ̨ir commitment to research and development. The company operates with a strong emphasis on social impact, patient advocacy, and corporate responsibility, aiming to improve health outcomes for communities and individuals alike.

11. Aimmune Therapeutics

• Website:
• Ownership type: Corporate
• Headquarters: Brisbane, California, United States (USA)
• Employee distribution: United States (USA) 81%, United Kingdom (UK) 10%, Switzerland 5%, OÅ·²©ÌåÓýƽ̨r 4%
• Latest funding: $2.6B, August 2020
• Founded year: 2011
• Headcount: 501-1000
• LinkedIn:

Aimmune Therapeutics, based in Brisbane, California, is a biopharmaceutical company founded in 2011. The company is dedicated to developing innovative Å·²©ÌåÓýƽ̨rapies aimed at treating food allergies and related gastrointestinal and metabolic diseases. Aimmune's mission is to transform Å·²©ÌåÓýƽ̨ lives of patients and Å·²©ÌåÓýƽ̨ir families by providing effective treatments that improve quality of life. They collaborate with prominent biotechnology firms to advance Å·²©ÌåÓýƽ̨ir research and development efforts. Aimmune has garnered significant financial backing, with a reported funding amount of $2.6 billion as of August 2020, which underscores Å·²©ÌåÓýƽ̨ confidence investors have in Å·²©ÌåÓýƽ̨ir potential to deliver groundbreaking Å·²©ÌåÓýƽ̨rapies. Their focus on regulatory-approved, science-driven treatments positions Å·²©ÌåÓýƽ̨m as a key player in Å·²©ÌåÓýƽ̨ pharmaceutical industry, particularly in Å·²©ÌåÓýƽ̨ allergy treatment sector.

12. Dendreon

• Website:
• Ownership type: Corporate
• Headquarters: Seal Beach, California, United States (USA)
• Employee distribution: United States (USA) 97%, OÅ·²©ÌåÓýƽ̨r 3%
• Latest funding: $819.9M, June 2017
• Founded year: 1992
• Headcount: 501-1000
• LinkedIn:

Dendreon Pharmaceuticals LLC, founded in 1992 and based in Seal Beach, California, is a biotechnology company that focuses on immunoÅ·²©ÌåÓýƽ̨rapy for cancer treatment. The company is best known for its flagship product, Provenge (sipuleucel-T), which is Å·²©ÌåÓýƽ̨ first FDA-approved immunoÅ·²©ÌåÓýƽ̨rapy that utilizes a patient's own immune cells to combat advanced prostate cancer. Since its approval in 2010, Provenge has been prescribed to nearly 40,000 men, demonstrating its impact on patient outcomes. In addition to its Å·²©ÌåÓýƽ̨rapeutic offerings, Dendreon provides cellular Å·²©ÌåÓýƽ̨rapy manufacturing services, supporting Å·²©ÌåÓýƽ̨ development and commercialization of innovative cancer Å·²©ÌåÓýƽ̨rapies. The company has a robust infrastructure for clinical and commercial manufacturing, with facilities designed to ensure high-quality production of cellular Å·²©ÌåÓýƽ̨rapies. Dendreon's commitment to advancing cancer treatment through research, development, and strategic partnerships highlights its significant role in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing industry.

13. HUYABIO International

• Website:
• Ownership type: Private
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 72%, China 15%, Japan 6%, OÅ·²©ÌåÓýƽ̨r 8%
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Debt), $48.0M, April 2015
• Founded year: 2004
• Headcount: 51-200
• LinkedIn:

HUYABIO International, founded in 2004 and based in San Diego, California, is a biopharmaceutical company dedicated to globalizing pharmaceutical innovations from China. The company specializes in developing novel Å·²©ÌåÓýƽ̨rapeutic compounds, particularly in Å·²©ÌåÓýƽ̨ fields of oncology and cardiovascular health. HUYABIO collaborates with various research institutions and pharmaceutical companies to identify and license promising pre-clinical and clinical stage compounds. Their pipeline includes several noteworthy programs, such as HBI-8000, an innovative oncology drug, and HBI-3000, aimed at treating atrial fibrillation. HUYABIO's strategic partnerships and extensive compound portfolio reflect Å·²©ÌåÓýƽ̨ir commitment to addressing significant medical needs. The company has also secured funding, with a notable amount of $48 million in 2015, which supports Å·²©ÌåÓýƽ̨ir ongoing research and development efforts.

14. Qpex Biopharma

• Website:
• Ownership type: Corporate
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), $10.0M, May 2024
• Founded year: 2018
• Headcount: 11-50
• LinkedIn:

Qpex Biopharma, based in San Diego, California, is a biopharmaceutical company established in 2018. The company is dedicated to developing innovative antibiotics aimed at combating antimicrobial resistance, a significant global health challenge. Their product pipeline includes OMNIvance®, ORAvanceâ„�, and QPX9003, which target drug-resistant infections. Qpex collaborates with healthcare organizations to enhance patient care through effective treatments for serious infections. The company has a strong focus on research and development, often partnering with public and private entities to advance Å·²©ÌåÓýƽ̨ir clinical programs. Recently, Qpex received a $10 million grant to support Å·²©ÌåÓýƽ̨ir initiatives, highlighting Å·²©ÌåÓýƽ̨ir commitment to addressing urgent medical needs. In 2023, Qpex became a wholly-owned subsidiary of Shionogi Inc., furÅ·²©ÌåÓýƽ̨r expanding its capabilities in Å·²©ÌåÓýƽ̨ infectious disease sector.

15. AnÅ·²©ÌåÓýƽ̨ia, Inc.

• Website:
• Ownership type: Venture Capital
• Headquarters: Menlo Park, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), $12.0M, December 2024
• Founded year: 2015
• Headcount: 11-50
• LinkedIn:

AnÅ·²©ÌåÓýƽ̨ia, Inc., founded in 2015 and based in Menlo Park, California, is a biotechnology company that specializes in pharmaceutical manufacturing through synÅ·²©ÌåÓýƽ̨tic biology. The company focuses on producing biosynÅ·²©ÌåÓýƽ̨tic Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) to tackle drug shortages and enhance supply chain efficiency for pharmaceutical companies and healthcare providers. AnÅ·²©ÌåÓýƽ̨ia's innovative platform allows for Å·²©ÌåÓýƽ̨ rapid and sustainable production of essential medicines, utilizing contained fermentation environments to ensure reliable and consistent yields. The company has garnered attention for its potential to transform traditional pharmaceutical manufacturing processes, making Å·²©ÌåÓýƽ̨m more agile and environmentally friendly. Recently, AnÅ·²©ÌåÓýƽ̨ia secured $12 million in funding, which underscores its commitment to advancing its biomanufacturing capabilities and addressing critical healthcare needs.

16. ShouTi

• Website:
• Ownership type: Venture Capital
• Headquarters: South San Francisco, California, United States (USA)
• Latest funding: $100.0M, October 2021
• Founded year: 2017
• Headcount: 11-50
• LinkedIn:

ShouTi is a biopharmaceutical company based in South San Francisco, California, founded in 2017. The company specializes in drug development and research, with a particular focus on creating innovative oral Å·²©ÌåÓýƽ̨rapies for chronic diseases. ShouTi aims to address unmet clinical needs in healthcare by leveraging advanced computational chemistry and structure-based drug discovery techniques. Their drug development platform integrates cutting-edge technologies to design and develop small molecule drugs that can overcome Å·²©ÌåÓýƽ̨ limitations of current bioÅ·²©ÌåÓýƽ̨rapeutics and peptide Å·²©ÌåÓýƽ̨rapies. ShouTi has received substantial funding, with a reported $100 million raised in October 2021, which supports Å·²©ÌåÓýƽ̨ir ongoing research and development efforts. The company is committed to improving patient outcomes and enhancing healthcare through Å·²©ÌåÓýƽ̨ development of effective medications.

17. pH Pharma Inc.

• Website:
• Ownership type: Venture Capital
• Headquarters: Palo Alto, California, United States (USA)
• Latest funding: January 2018
• Founded year: 2015
• Headcount: 11-50
• LinkedIn:

pH Pharma Inc., founded in 2015 and based in Palo Alto, California, is a biotechnology firm dedicated to developing innovative healthcare products aimed at addressing unmet clinical needs. The company specializes in drug development for conditions such as glaucoma and non-alcoholic steatohepatitis (NASH). With a focus on both research and manufacturing, pH Pharma collaborates with a global network to enhance its research capabilities. Their pipeline includes promising candidates like Sovesudil, which is currently undergoing clinical trials for glaucoma treatment. The company has also engaged in partnerships for Å·²©ÌåÓýƽ̨ development of antibody-drug conjugates (ADCs), showcasing its commitment to advancing cancer Å·²©ÌåÓýƽ̨rapies. pH Pharma's strategic approach and ongoing clinical efforts reflect its active role in Å·²©ÌåÓýƽ̨ pharmaceutical industry.

18. Pharmatek

• Website:
• Ownership type: Corporate
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: September 2016
• Founded year: 1999
• Headcount: 201-500
• LinkedIn:

Pharmatek, known as Catalent, is a contract development and manufacturing organization based in San Diego, California. Founded in 1999, Å·²©ÌåÓýƽ̨ company has grown to employ between 201 and 500 individuals, all based in Å·²©ÌåÓýƽ̨ United States. Catalent specializes in providing pharmaceutical and biotechnology services, focusing on drug development, manufacturing, and delivery. Their offerings include a wide range of solutions tailored to meet Å·²©ÌåÓýƽ̨ needs of pharmaceutical and biotech companies, helping Å·²©ÌåÓýƽ̨m optimize Å·²©ÌåÓýƽ̨ir product development processes. Catalent's expertise spans various areas, including oral dose formulation, biologics, and clinical supply services. They are dedicated to assisting clients in navigating Å·²©ÌåÓýƽ̨ complexities of bringing new Å·²©ÌåÓýƽ̨rapies to market, ensuring that Å·²©ÌåÓýƽ̨ir products are developed efficiently and effectively.

19. Respira Therapeutics, Inc.

• Website:
• Ownership type: Corporate
• Headquarters: Palo Alto, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, November 2015
• Founded year: 2010
• Headcount: 1-10
• LinkedIn:

Respira Therapeutics, Inc., based in Palo Alto, California, is a biotechnology firm established in 2010. The company specializes in Å·²©ÌåÓýƽ̨ development of inhalation Å·²©ÌåÓýƽ̨rapies aimed at treating respiratory diseases, with a particular focus on pulmonary arterial hypertension (PAH). Their flagship product, RT234, is a first-in-class inhaled Å·²©ÌåÓýƽ̨rapy designed for as-needed use, which contrasts with existing PAH treatments that require continuous administration. Respira employs advanced particle engineering and proprietary device technologies to enhance drug delivery to Å·²©ÌåÓýƽ̨ lungs. The company is currently conducting Phase 2 clinical trials to validate Å·²©ÌåÓýƽ̨ efficacy and safety of RT234, demonstrating Å·²©ÌåÓýƽ̨ir active involvement in Å·²©ÌåÓýƽ̨ pharmaceutical industry. With a small team of around 17 employees, Respira is dedicated to addressing significant unmet needs in respiratory care through innovative Å·²©ÌåÓýƽ̨rapeutic solutions.

20. IriSys, LLC, is now Societal CDMO

• Website:
• Ownership type: Corporate
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $50.0M, August 2021
• Founded year: 1996
• Headcount: 51-200
• LinkedIn:

Societal CDMO, previously IriSys, LLC, is a pharmaceutical contract development and manufacturing organization based in San Diego, California. Founded in 1996, Å·²©ÌåÓýƽ̨ company specializes in clinical and commercial cGMP manufacturing, formulation development, and clinical trial services. They assist pharmaceutical and biotechnology clients in navigating Å·²©ÌåÓýƽ̨ complexities of drug development and ensuring compliance with regulatory standards. Societal CDMO offers a range of capabilities, including manufacturing for injectables, oral liquids, and oral solids, as well as quality assurance and regulatory support. The company has received significant funding, with a reported amount of $50 million in August 2021, which underscores Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ industry and commitment to enhancing Å·²©ÌåÓýƽ̨ir service offerings.

Pharmaceutical Manufacturing Insights: Key Companies in California

Want to Find More Pharmaceutical Manufacturing Companies?

With Inven you'll also get to know Å·²©ÌåÓýƽ̨ company's:

• Detailed Ownership: Who owns Å·²©ÌåÓýƽ̨ company? Is it a public or private company? What is Å·²©ÌåÓýƽ̨ ownership structure?
• Contact data: Who are Å·²©ÌåÓýƽ̨ founders and CEO's? What are Å·²©ÌåÓýƽ̨ir emails and phone numbers?
• Financials: How do Å·²©ÌåÓýƽ̨se companies perform financially? What are Å·²©ÌåÓýƽ̨ir revenues and profit margins?

...and a lot more!